289 related articles for article (PubMed ID: 37344261)
1. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA
Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.
Wong HL; Tworkoski E; Ke Zhou C; Hu M; Thompson D; Lufkin B; Do R; Feinberg L; Chillarige Y; Dimova R; Lloyd PC; MaCurdy T; Forshee RA; Kelman JA; Shoaibi A; Anderson SA
Vaccine; 2023 Jan; 41(2):532-539. PubMed ID: 36496287
[TBL] [Abstract][Full Text] [Related]
3. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study.
Ab Rahman N; Lim MT; Lee FY; Lee SC; Ramli A; Saharudin SN; King TL; Anak Jam EB; Ayub NA; Sevalingam RK; Bahari R; Ibrahim NN; Mahmud F; Sivasampu S; Peariasamy KM;
Vaccine; 2022 Jul; 40(32):4394-4402. PubMed ID: 35667917
[TBL] [Abstract][Full Text] [Related]
4. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
[TBL] [Abstract][Full Text] [Related]
5. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
7. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
[TBL] [Abstract][Full Text] [Related]
8. Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
Yamin D; Yechezkel M; Arbel R; Beckenstein T; Sergienko R; Duskin-Bitan H; Yaron S; Peretz A; Netzer D; Shmueli E
Lancet Infect Dis; 2023 Oct; 23(10):1130-1142. PubMed ID: 37352878
[TBL] [Abstract][Full Text] [Related]
9. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
10. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
[TBL] [Abstract][Full Text] [Related]
11. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
[TBL] [Abstract][Full Text] [Related]
12. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
[TBL] [Abstract][Full Text] [Related]
13. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
14. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
[TBL] [Abstract][Full Text] [Related]
15. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
[TBL] [Abstract][Full Text] [Related]
16. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
17. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
Yasmin F; Najeeb H; Naeem U; Moeed A; Atif AR; Asghar MS; Nimri N; Saleem M; Bandyopadhyay D; Krittanawong C; Fadelallah Eljack MM; Tahir MJ; Waqar F
Immun Inflamm Dis; 2023 Mar; 11(3):e807. PubMed ID: 36988252
[TBL] [Abstract][Full Text] [Related]
18. Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell's Palsy: A Nested Case-Control and Self-Controlled Case Series Study.
Wan EYF; Chui CSL; Ng VWS; Wang Y; Yan VKC; Lam ICH; Fan M; Lai FTT; Chan EWY; Li X; Wong CKH; Chung RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Lau CS; Leung GM; Wong ICK
Clin Infect Dis; 2023 Feb; 76(3):e291-e298. PubMed ID: 35675702
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
20. Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
Lu Y; Matuska K; Nadimpalli G; Ma Y; Duma N; Zhang HT; Chiang Y; Lyu H; Chillarige Y; Kelman JA; Forshee RA; Anderson SA
JAMA; 2024 Mar; 331(11):938-950. PubMed ID: 38502075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
